Compare · LXEO vs RVMD
LXEO vs RVMD
Side-by-side comparison of Lexeo Therapeutics Inc. (LXEO) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LXEO and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $41.48B, about 192.2x LXEO ($215.8M).
- Both names hit the wire about 12 times in the past 4 weeks.
- RVMD has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- Lexeo Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- $215.8M
- $41.48B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2020
- News (4w)
- 12
- 12
- Recent ratings
- 11
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest LXEO
- SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.
- Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
- Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 4 filed by Chief Financial Officer Tamayo Louis Edward
- Chief Operating Officer Otero Jose Manuel was granted 2,110 shares, increasing direct ownership by 2% to 138,288 units (SEC Form 4)
- Chief Medical Officer Bhalla Narinder Pal was granted 2,714 shares, increasing direct ownership by 3% to 84,908 units (SEC Form 4)
- Chief Executive Officer Townsend Richard Nolan was granted 2,306 shares, increasing direct ownership by 0.62% to 376,778 units (SEC Form 4)
- Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
- Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Latest RVMD
- William Blair initiated coverage on Revolution Medicines
- Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Chief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)
- SVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)
- Officer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)